Critical Review

Oncoplastic breast surgery in the setting of breast-conserving therapy: A systematic review

Jennifer J. Yoon BA, William Ross Green MD, Sinae Kim PhD, Thomas Kearney MD, Bruce G. Haffty MD, Firas Eladoumik MD, Sharad Goyal MD,*

a Department of Radiation Oncology, New Brunswick, New Jersey
b Biometrics Division, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
c Division of Surgical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey

Received 15 March 2016; received in revised form 15 August 2016; accepted 14 September 2016

Abstract
Breast-conserving therapy (BCT), or breast-conserving surgery with adjuvant radiation therapy, has become a standard treatment alternative to mastectomy for women with early-stage breast cancer after many long-term studies have reported comparable rates of overall survival and local control. Oncoplastic breast surgery in the setting of BCT consists of various techniques that allow for an excision with a wider margin and a simultaneous enhancement of cosmetic sequelae, making it an ideal breast cancer surgery. Because of the parenchymal rearrangement that is routinely involved in oncoplastic techniques, however, the targeted tissue can be relocated, thus posing a challenge to localize the tumor bed for radiation planning. The goals of this systematic review are to address the challenges, outcomes, and cosmesis of oncoplastic breast surgery in the setting of BCT.

Copyright © 2016 the Authors. Published by Elsevier Inc. on behalf of the American Society for Radiation Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

Breast-conserving surgery (BCS), or partial mastectomy with adjuvant radiation therapy (ART), has become a standard treatment alternative to mastectomy for women with early-stage breast cancer after many long-term studies have reported comparable rates of overall survival and local control. In BCS, the removal of the tumor leaves a postsurgical deformity, or cavity, which can have a major effect on cosmesis. As surgical techniques advanced in the early 1990s, Audretsch introduced “oncoplastic breast surgery,” an integration of plastic surgery techniques with BCS to reduce cosmetic defect following partial mastectomy.

Oncoplastic breast surgery consists of various techniques that allow for an excision with a wider margin and a simultaneous enhancement of cosmetic sequelae, making it an ideal breast cancer surgery. A 2008 audit of a specialist breast practice reported that breast reconstruction and oncoplastic operations accounted for 28% of all...
breast-cancer related procedures, indicating a rising utilization of oncoplastic breast surgery. The surgical techniques used in oncoplastic breast surgery in the setting of breast conservation can be largely divided in 2 categories: volume displacement (VD) and volume replacement (VR). Appropriate technique is chosen based on patient and tumor characteristics because the outcomes of the surgery may depend on the type of technique.

Adjuvant therapy, however, is ideally not affected by the surgical technique. Breast-conserving therapy (BCT), which consists of BCS followed by whole breast irradiation (WBI), has been long established as a standard alternative to mastectomy. A total dose of 45 to 50 Gy in 25 daily fractions of 1.8 to 2 Gy over 5 weeks and a total of 10 to 16 Gy in 5 to 8 fractions are the conventional delivery schedules for WBI and boost irradiation, respectively. Hypofractionated WBI, which consists of higher fraction doses (≥2 Gy) delivered in fewer fractions over a shorter treatment course, is an alternative treatment to the conventional WBI in the setting of BCT. A total dose of 40 to 44 Gy in 13 to 16 fractions over 3 weeks is the conventional delivery schedule for hypofractionated WBI. The tumor-bed boost can be administered after WBI to reduce local recurrence rates in the setting of BCT. The use of boost after WBI has been demonstrated in multiple randomized studies to decrease local recurrences. Because younger women are at a greater risk of local recurrence, and women who undergo oncoplastic breast surgery tend to be of younger age, a boost would be of greater benefit to them in terms of local control.

In addition to the conventional BCT, considerable variations exist in delivering radiation therapy (RT) after oncoplastic breast surgery. Recently, the use of Accelerated Partial Breast Irradiation (APBI) has been demonstrated as a possible alternative to WBI for patients who meet the selection criteria. By targeting specifically the tumor cavity within a shorter period, APBI offers potential benefits by decreasing radiation dose delivered to normal tissue outside of the target volume and increasing accessibility of treatment to patients.

Because of the parenchymal rearrangement that is routinely involved in oncoplastic techniques, however, the targeted tissue can be relocated, posing a challenge to localize the tumor bed. Moreover, the boost irradiation may diminish cosmesis, which would offset the principal goal of oncoplastic breast surgery to enhance posttreatment cosmesis. To determine the optimal type of RT after oncoplastic BCS, the specific delivery method including the dosage, fraction, and timing needs to be reported in detail. This systematic review aims to address the outcomes of oncoplastic BCS with adjuvant breast RT by evaluating local control and cosmetic sequelae to optimize future treatment plans for patients with breast cancer.

### Methods

A comprehensive literature search of PubMed was performed using combinations of the following search terms: oncoplastic breast surgery, breast conserving surgery, breast cancer, RT, radiotherapy, volume displacement, volume replacement, breast tissue rearrangement, and breast reconstruction in articles published between January 1995 and January 2015. Trials eligible for this review included randomized control trials, cohort studies, and retrospective series. The titles and abstracts of the potentially relevant publications (n = 1194) were examined to include only English-language studies that report oncoplastic breast surgery followed by RT, and to eliminate studies that fall under the following exclusion criteria: (1) including only surgical techniques; (2) case reports or reviews; (3) participating number of patients <30; and (4) involving complete mastectomy. Qualified studies were then cross-referenced until the search strategy was exhausted. Among 109 articles that were initially identified for full review, 41 were selected for inclusion (Table 1). The remaining 68 articles were not included because of the use of tissue expander or implants, preoperative RT, techniques involving lipofilling, prior history of breast augmentation, and lack of cosmesis report and/or recurrence rate. The rates of satisfaction rating or local recurrence used in the analysis were calculated based on the number of patients with such events provided in each study. A generalized linear mixed model with a random effect on study was used to estimate the overall probabilities of events of interest. Estimated probabilities along with 95% confidence intervals (CIs) were reported. All statistical analyses were performed using SAS 9.4 (Cary, NC).

### Results

#### Surgical techniques used in oncoplastic BCS

As mentioned previously, oncoplastic BCS can be largely divided in 2 types of surgical techniques: VD and VR. VD involves mobilizing local glandular flaps and redistributing them to the resection defect, resulting in a net loss of breast volume. Using this principle of VD, reduction mammoplasty can be performed on patients with large breasts. On the other hand, VR relies on harvesting autologous tissue from a remote site and transferring the flap into the resection defect while preserving breast volume. Women with small breasts or large tumor/breast ratio may not be suitable candidates for VD, because they do not have sufficient breast tissue to be redistributed to the resected region. For these women, VR may serve as an alternative by using tissue from a remote site to reconstruct the resection defect; however, should they require a complete mastectomy in the future,
Table 1  Patient demographics and tumor characteristics

| Study                  | Patient no. | Tumor stage | Tumor size (range, mm) | Mean tumor size (range, g) | Mean specimen weight (range, g) | Positive margins (%) | Oncoplastic surgery |
|------------------------|-------------|-------------|------------------------|-----------------------------|---------------------------------|----------------------|---------------------|
| Niazz et al, 2015      | 72          | 57 (36-78)  | pTis (6%), pT1a-1b (10%), pT1c (38%), pT2 (40%) | 17.2 (1-90)                 | 110 (17-903)              | 0 (22.8%), I (23.3%), IIA (28.7%) | VD (RM)            |
| Roth et al, 2014       | 134         | —           | pNx (10%), pN0 (88%), pN1mi (2%), pN1b (1%) | ER + PR - 79                | 14 (3-35)                  | 0       | VD                 |
| Yang et al, 2011       | 58          | 46          | 0 (17%), I (55%), Ib (17%), Ib (10%) | —                            | —                              | —       | VD                 |
| Caruso et al, 2008     | 61          | 45.3        | pT1a (3%), pT1b (10%), pT1c (44%), pT2 (41%), pT4 (2%) | 53 (34-70)                 | 150 (28-484)              | 4.7         | VD (RM)            |
| Maguire, 2012          | 79          | 61.9 (34-97.6) | 0 (9.2%), I (60.5%), IIA (17.1%), IIB (9.2%), IC (9.2%), T1 (9.2%), T1b (7.4%), T2 (16.0%) | 10/28                      | —                            | —       | RM**               |
| Lee et al, 2014        | 213         | 45.7 (23-65) | 0 (8.3%), I (45.4%), IA (28.7%), IB (11.1%), IIA (11.1%), IIB (11.1%), IIC (11.1%) | 77.5 (7.5-150)             | 148.4 (50-408)         | 0 (7.5-150) | VD                  |
| Gendy et al, 2003      | 49          | 48 (34-69)  | N0 (71%), N1 (27%), NA (2%) | —                            | —                              | —       | VR                 |
| Losken et al, 2004     | 39          | 49 (28-73)  | 0 (5%), T1N0 (49%), T1N1 (5%), T2N0 (13%), T2N1 (13%), T3N0 (9%), T3N1 (5%), IV (9%) | 12.8 (12.8-20)            | 26 (2-65)                  | 0       | VR                 |
| Massa et al, 2015      | 32          | ERT 16      | T1b - T2              | —                            | —                              | —       | RM*                |
| Silverstein et al, 2015| 311         | Standard, 245 | extreme, 66          | —                            | —                              | —       | RM**               |
| Egro et al, 2015       | 117         | 53.6        | 0 (15.4%), I (41.9%), II (9.4%), III (3.6%), IV (3.6%), unknown (3.6%) | 19/46                      | 17                            | 52.4     | RM                 |
| Eaton et al, 2014      | 86          | 53 (34-80)  | Tis (13%), T1 (47%), T2 (30%), T3 (6%), T4 (3%), N0 (76%), N1 (21%), N2 (2%), N3 (1%) | ER + PR - 59               | —                            | —       | RM                 |
| Schenk et al, 2006     | 121         | 59.2 (33-78) | DCIS III (9%), T1a (2%), T1b (9%), T1c (28%), T2 (40%), T3N0 (9%), T4 (1%) | ER + PR - 66               | 12/29                       | 267.6 (267.6-1090) | RM*                |
| Goffman et al, 2005    | 57          | —           | T1 (33%), T2 (35%), T3 (12%), T4 (9%) | —                            | 1.6/2                         | 0       | RM                 |
| Chang et al, 2004      | 37          | 52 (34-77)  | 19/46                  | —                            | —                              | —       | RM                 |
| Mungo et al, 2006      | 74          | 46.6 (29-69) | T1 (55%), T2 (45%) | —                            | —                              | —       | RM                 |
| Clough et al, 2003     | 101         | 53 (31-91)  | T1N0 (6%), T1N1 (12%), T2N0 (50%), T2N1 (20%), T3N0 (20%), T3N1 (40%), T4N0 (30%) | 16.8/2                     | 32 (10-70)                  | 222 (20-1900) | RM                 |
| Nos et al, 2009        | 50          | 53 (35-69)  | N1 (44%), N2 (44%), N3 (12%) | —                            | 269 (269-736)              | 0       | TM                 |
| Niazz et al, 2007      | 63          | 47 (11-75)  | 0 (25%), I (38%), II (10%), III (11%), LNP (19%) | —                            | —                              | —       | RM                 |
| McCalley and Moomian, 2005| 50          | 53 (35-69)  | N1 (44%), N2 (44%), N3 (12%) | —                            | —                              | —       | TM                 |
| Fitoussi et al, 2010   | 540         | 52 (28-90)  | 0 (22.8%), I (23.8%), II (32.6%), II (15.6%), III (2.1%), III (1.6%), III (1.7%), III (1.7%), III (1.7%) | 17.2/2                     | 29.1 (4-100)                | 187.7    | TM                 |
| Chakraverty et al, 2012| 146         | 59 (26-83)  | T1 (46%), T2 (48%), T3 (6%) | 25/35                       | 21 (1-98)                   | 67 (11-1050) | TM                 |
| Caruso et al, 2011     | 50          | —           | Stage 0 [Tis, N0, M0] (3.8%), ER + PR - 22 | 17                           | 2 (17-22)                  | 0       | TM                 |

(continued on next page)
reconstruction with autologous tissue will not be an option.28,29 Because of potential donor site morbidity associated with VR30,31 and restrictions on possible future surgeries,28,29 VD is a preferred method when patients meet the criteria. Among the studies included in our review, 37 involved the use of VD, whereas only 11 involved VR.

### Table 1 (continued)

| Study                        | Patient no. | Mean age (range) | Tumor stage | Receptor status (%) | Chemotherapy (neoadjuvant/ adjuvant, %) | Mean tumor size (range, mm) | Mean specimen weight (range, g) | Positive margins (%) | Oncoplastic surgery |
|------------------------------|-------------|------------------|-------------|---------------------|----------------------------------------|----------------------------|-----------------------------|---------------------|---------------------|
| Meretoja et al, 201054       | 68          | 57 (37-80)       | —           | 1 hormonal receptor, 82 | —                                      | —                          | —                           | —                   | VD (20)             |
| Rietjens et al, 200755       | 148         | 50 (31-71)       | pTis (7%), pT1a (10%), pT1c (41%), pT2 (40%) |
|                              |             |                  |             | 40%                  | 25%                                    | 15.4                       | 198 (20-2100)              | 4.7                 | RM (48)             |
| Grubnik et al, 201356        | 251         | 56.3 (28-80)     | Tis (10%), T1a (2%), T1b (19%), T1c (36%), T2 (29%), T3 (1%), T4(3%) |
|                              |             |                  |             | ER+ /PR+ /HER2+      | 70/—                                   | 23.9                       | 0 VD                        | 0 TM                |
| Bogusevicus et al, 201457    | 60          | 55.8 (33-84)     | IIA (61.7%), IIIA (23.3%), IIIB (15%), T1N2 (8.4%), T2N2 (13.7%), T3N1 (16.7%), T4N2 (3.3%), T4N1 (13.3%), T4N2 (6.7%), any T3N3 (1%) |
|                              |             |                  |             | ER+ /PR+ /HER2+      | 70/—                                   | 23.9                       | 0 VR                        | 0 ER                |
| Down et al, 201360          | 37          | 57 (35-86)       | —           | —                   | —                                      | 231.1                      | 0 VD (18)                  | 0 VR (19)           |
| Kronowitz et al, 200661      | 50          | —                | —           | —                   | —                                      | —                          | —                           | —                   | VD (14)             |
| Tensofsky et al, 201462      | 58          | 60.9 (35-85)     | —           | —                   | —                                      | 11.0 (0.50)                | 0 ER                        | 0 RM (3)            |
| Hamdi, 201357               | 119         | 48 (31-69)       | —           | —                   | —                                      | —                          | —                           | —                   | VD (26)             |
| Vega et al, 201158           | 45          | 52 (33-72)       | —           | —                   | —                                      | —                          | —                           | —                   | RM (11)             |
| Munhoz et al, 201163         | 106         | 48.6 (29-68)     | —           | —                   | —                                      | 342 (87-910)              | 1.8                         | —                   | RM (48)             |
| Bamford et al, 201564        | 68          | 52 (36-77)       | —           | ER+ /PR+ /HER2+      | 22.1 (3.85)                            | 436.7 (123-1330)           | 0 TM                        | —                   | ER (11)             |
| Khafagy et al, 201265        | 30          | 51.86 (30-70)    | LNP (56.7%) | ER+ /PR+ /HER2+      | 22.1 (3.85)                            | 436.7 (123-1330)           | 0 TM                        | —                   | ER (11)             |
| Chang et al, 201266          | 79          | 53.6 (18%), I (14%), II (41%), III (22%), and IV (2%); phyllodes (2%) |
|                              |             |                  |             | ER+ /PR+ /HER2+      | 47/15                                  | 0                          | —                           | —                   | RM (48)             |
| Munhoz et al, 200970         | 218         | 49 (23-71)       | —           | —                   | —                                      | 22 (5.5)                   | 362 (89-880)              | 0 RM (48.2%)         |
| Munhoz et al, 200671         | 39          | T1 (51%), T2 (49%) |
|                              |             |                  | —           | —                   | —                                      | 590 (200-910)             | 0 RM (48.2%)              | —                   | RM (48.2%)          |
| Munhoz et al, 200672         | 34          | T1 (65%), T2 (35%) |
|                              |             |                  | —           | —                   | —                                      | 310 (215-550)             | 0 VR (48.2%)              | —                   | RM (48.2%)          |

ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; LNP, lymph nodal positivity; N, nodal status; NR, not reported; PR, progesterone receptor; RM, reduction mammoplasty; T, tumor size; VD, volume displacement; VR, volume replacement.

* patients who received ERT

** patients who received IORT

Comparison of local recurrences and cosmetic outcomes between VD and VR

A total of 4170 patients were included in 41 studies. The range of patients’ mean age in 41 studies was 45 to 62 years. The range of average tumor size was 11 to 77 mm (extreme oncoplasty was performed on a mean tumor
size of 77 mm in Silverstein et al\textsuperscript{32) and the range of average specimen weight was 84 to 653 g. Nodal status was reported in 17 studies. The majority of the patients had nodal status of N0 in 13 studies (range, 68-88%), and only 8 studies reported nodal positivity, 4 of which reported N3 (range, 1-15%). The surgical techniques involved 2 methods: VD (n = 37) and VR (n = 11). Reduction mammoplasty (n = 23) and therapeutic mammoplasty (n = 8) were categorized under VD (Table 1).

Of the 37 studies that implemented VD, 34 reported follow-up data. The mean follow-up in these studies was 39 months (range, 1-262 months). The local recurrence rate was reported in 35 studies (range, 0%-10%). The distant recurrence rate was reported in 23 studies (range, 0%-38.3%) and the mortality rate was reported in 19 studies (range, 0%-23%). Patient-rated cosmesis was reported in 17 studies and professional rating on cosmesis was reported in 18 studies. In the 17 studies that included patient cosmesis, 70% to 100% of patients reported excellent/good satisfaction. In the 18 studies that involved professional rating, excellent/good satisfaction was reported 57% to 96% of the time. The type of RT was identified in all studies (35 studies used WBI and 2 studies used APBI), although the dose-fractionation was reported in only 16 studies, with daily fractions over 5 weeks that ranged of from a total of 45 to 52 Gy. The use of boost RT was reported in 17 studies. The dose for boost RT with a range of 10 to 15 Gy was reported in 13 studies, whereas the fractionation schedule was reported only in 3 studies (Table 2).

Of the 11 studies that used VR, the mean follow-up, reported in 10 studies, was 40 months (range, 3 to 120 months). The local recurrence rate was reported in 10 studies (range, 0%-10%). The distant recurrence rate was reported in 2 studies (range, 10.3%-38.3%), and the mortality rate was reported in 2 studies (range, 5.1%-23.3%). Patient rating on cosmesis was reported in 6 studies and professional rating on cosmesis was also reported in 6 studies. Excellent/good cosmesis rating by the patients ranged from 82.3% to 92.3%, which was higher than that reported by professionals (33% to 87.2%). The type of RT was identified in all studies (all 11 studies used WBI), although the dose-fractionation was reported in only 5 studies, with daily fractions over 5 weeks ranging from a total of 45 to 52 Gy. The use of boost RT was reported in 3 studies, all of which reported a range of 10 to 15 Gy without specified fractionation schedule (Table 3).

### Use of WBI after oncoplastic BCS

WBI along with tumor-bed boost irradiation has been long established as a standard adjuvant therapy for BCS\textsuperscript{12-14,33}. The delivery schedule for WBI involves whole breast radiation to a total dose 45 to 50 Gy in 25 daily fractions of 1.8 to 2 Gy over 5 weeks, and was delivered to suitable patients (range, 62.7%-100%) in studies that provided adjuvant RT schedules. Patient refusal of recommended treatment was the main reason that adjuvant RT was not delivered in up to 37.3% in some studies. Hypofractionated WBI, which consists of higher fraction doses (>2 Gy) delivered in fewer fractions over a shorter treatment course, is an alternative treatment to the conventional WBI in the setting of BCT\textsuperscript{11}. Although not all studies reported their fractionation scheme, those that reported it used the conventional scheme of a total dose of 40 to 44 Gy in 13 to 16 fractions over 3 weeks.

A total of 23 studies were identified that included data on local recurrences for patients who underwent oncoplastic BCS with WBI. Two studies were excluded from this analysis because of discrepancies between total number of patients and the number of patients receiving RT, as well as not providing information about local recurrence rates. As a result, only 21 studies were included in this analysis. The overall estimated probability of local recurrence when whole breast radiation was delivered after oncoplastic breast surgery was 0.015 (95% CI, 0.008-0.03).

Professional ratings regarding cosmesis were reported in 10 studies in patients who underwent oncoplastic BCS followed by WBI. The rating scales varied across studies, and cosmesis ratings >60%, 50%, and 66% were considered as satisfactory in 5-, 4-, and 3-point rating scale, respectively. The overall estimated probability of satisfaction based on professional ratings was 0.877 (95% CI, 0.784-0.934). Eight studies included data regarding patient rating of cosmesis. The overall estimated probability of satisfaction based on patient ratings was 0.913 (95% CI, 0.815-0.962).

### Use of local boost RT after oncoplastic BCS

For early-stage breast cancer, local recurrences occur most commonly around the tumor bed\textsuperscript{12-14}. The use of boost after whole breast radiation has been demonstrated in multiple randomized studies to decrease local recurrence\textsuperscript{12-14,33}; therefore, it is reasonable to extrapolate that a local recurrence in the setting of oncoplastic BCS would be able to be minimized by administering the tumor-bed boost RT after WBI. However, because of the parenchymal rearrangement that is routinely involved in oncoplastic techniques, possible tissue relocation poses a challenge to localize the tumor bed for administration of boost radiation\textsuperscript{12,25}. Moreover, the additional radiation exposure from the boost RT may potentially exacerbate cosmetic defect, which would offset the principal goal of oncoplastic BCS to enhance posttreatment cosmesis\textsuperscript{26,27}. The use of boost RT was reported in 15 studies, most of which used the conventional delivery schedule of a total of 10 to 16 Gy in 5 to 8 fractions. Three studies with
### Table 2: Outcomes of volume displacement and RT

| Study | Patients receiving RT (%) | RT dose-fractionation (Gy) | Patients receiving boost RT | Boost RT dose-fractionation (Gy) | Patient rating on cosmesis | Professional rating on cosmesis | Local recurrence (%) | Distant recurrence (%) | Mortality (%) | Mean follow-up (mo, range) |
|-------|---------------------------|---------------------------|----------------------------|---------------------------------|---------------------------|-------------------------------|---------------------|------------------------|--------------|------------------------|
| Nierz et al., 2015[10] | 94.4 | 41.6 Gy in 13 fx (6/42.4 Gy in 20 fx (1/42.5 Gy in 16 fx (13) Gy in 20 fx (3) Gy in 23 fx (1), 3 Gy in 25 fx (5)) | 80.6 | 6.6 Gy in 1 fx | — | — | 14 | 14 | 0 | (19-51) |
| Roth et al., 2014[11] | 100 | PDR: 32 Gy (BID in 4 Gy fx) | — | — | — | — | 0.7 | 2.2 | 2.2 | (40-106) |
| Yang et al., 2011[12] | 100 | 50 | — | 10 | — | — | — | — | — | 21 |
| Caruso et al., 2008[13] | 100 | 50 | 50 | 10 | — | — | 93% excellent/good at 12 mo | 83% excellent/good at 12 mo | 0 | — | 1.6 |
| Ballester et al., 2005[14] | 100 | 50 | 10 | — | — | — | — | — | — | 35 |
| Rafter and Tausch, 2009[15] | 100 | Median: 46 (in 1.8 Gy fx) | 0 | 0 | 88% excellent/good between 1-3 years postsurgery | — | 0 | 0 | — | — |
| Maguire, 2007[16] | 59.3 | 50 | 95.3 | 10 | — | — | — | — | — | 24 |
| Khafagy et al., 2007[17] | 100 | 45 (range: 45-54) in 1 Gy fx | 58.1 | 14.92 (range: 6.42-20) in 2.14 Gy fx | — | — | 1.7 | — | — | 48 (6-120) |
| Massa et al., 2007[18] | 100 | 4550 (in 1.8-2 Gy fx) 5 times/wk | 18.21** | — | 80% excellent | — | — | 0** | 12.5** | 0** | — |
| Silverstein et al., 2015[19] | 100 | 10-16 (in 5-8 Gy fx) over 1-1.5 wk** | 0** | 100% favorable (scores >6)** | — | 0** | 0** | 0** | — | 35** |
| Egor et al., 2015[20] | 100 | 100%** | 100% | 100%** | — | — | 1.2** | — | — | 24** |
| Eaton et al., 2014[21] | 100 | 45 (range: 45-54) in 1 Gy fx | 58.1 | 14.92 (range: 6.42-20) in 2.14 Gy fx | — | — | — | 7.0 | 2.3 | 4.7 |
| Schenk et al., 2006[22] | 92.6 | 92.6 | — | 92.6 | 80% excellent | Mean 8.7 (range, 5-10) | 0 | 2.5 | 1.7 | 32 (11-106) |
| Goffman et al., 2005[23] | 84.2 | 50.40 | — | 10 | 38% excellent, 34% very good, 22% good, 2% fair, 4% poor | 3.5 | 7 | 3.5 | 19.2 |
| Chang et al., 2004[24] | 100 | 100 | — | 70% excellent | — | 0 | 0 | — | — | — |
| Munhoz et al., 2006[25] | 100 | Maximum 45-50 in daily fx | 100 | 100 | Good/very good in 81%, satisfactory in 16.2%, and poor in 2.7% | — | — | 0 | 0 | 22 (6-69) |
| Clough et al., 2003[26] | 87.1 | — | 5 | — | 88% acceptable at 2 y; 82% acceptable at 5 y | — | — | 0 | 0 | 39 |
| Losken et al., 2007[27] | 73 | — | — | 95% acceptable at 6 mo, average, 4.2 | 96% excellent/good/satisfactory | 0 | 0 | 13 (3-32) |
| McCukey and Macmillan, 2005[28] | 92 | — | — | — | 4% poor | 6 | 14 | 10 | 48 (14-140) |
| Nis et al., 1998[29] | 76 | 52 (range: 47-56) over 5 wk | 6 | — | 92% satisfactory at 1 y | 6 | 14 | 10 | 48 (14-140) |
| Fitousi et al., 2010[30] | 74 | 10 | — | 90.3% satisfactory at 1 y | — | 6 | 7.1 | 49 (6-262) |
| Chakravarty et al., 2012[31] | 90 | — | — | — | — | 2.7 | 1.3 | — | 28 (6-81) |
| Caruso et al., 2011[32] | 100 | 50 | 100 | 10 | — | — | 2 | 2 | 2 | 72.6 (32-168) |
| Merrer et al., 2010[33] | 90.8 | 90.8 | — | — | 84% acceptable (patient/professional unspecified) | 0 | 0 | 4.4 | 1.5 | 26 (6-52) |
| Grabnik et al., 2013[34] | 100 | Maximum 50 (in 25 fx) | 0 | 0 | 70% happy, 25% satisfied, 6% dissatisfied | — | — | 2.4 | 1.2 | 3.2 |
| Boguszaewicz et al., 2014[35] | 100 | Minimum 50 (in 25 fx) | 10-15 | 92.3% excellent/good | 96% acceptable (excellent/good)/fair | 10 | 38.3 | 23.3 | 86 |
| Kronowitz et al., 2006[36] | 100 | Minimum 50 | 10-15 | 87.2% excellent/good | 57% excellent/good | 2 | — | — | 29 |
boost RT and 3 studies without boost RT were used to estimate the professional cosmetic ratings. The overall estimated probability of satisfaction from professional cosmetic ratings was 0.849 (95% CI, 0.645-0.946) and 0.936 (95% CI, 0.03-0.999) with boost and without boost, respectively. Three studies with boost RT and 2 studies without boost RT were used to estimate the patient generated cosmetic ratings. The estimated probability of satisfaction from patient cosmetic rating was 0.89 (95% CI, 0.596-0.979) and 0.84 (95% CI, 0.1-0.996) with and without the boost, respectively. These estimates were not conclusive for the purpose of direct comparison because the analysis was performed on a small number of studies that used different rating systems. The effects of boost RT, which appeared to increase patient rating on cosmesis but decrease professional rating, may be attributable to the limitations of the estimates. Although a similar comparison in local recurrence rates was attempted to be drawn between patients with and without boost, a meaningful comparison was not feasible because of the limitations in available data and inconsistencies in reporting of the follow-up period.

### Use of APBI after oncoplastic BCS

APBI is typically delivered in 10 fractions over 5 days, twice daily, separated by at least 6 hours. A potential benefit derived from APBI is the decrease in the radiation dose delivered outside the targeted area because the treatment volume is the tumor cavity plus margin.24 The accelerated fractionation scheme also allows for increasing accessibility of treatment to patients.24 APBI may be performed using interstitial multicatheter brachytherapy, single-lumen balloon catheter brachytherapy, intracavitary multiple lumen catheter brachytherapy, 3-dimensional conformal external beam RT, or intraoperative RT (IORT).35 A typical external beam APBI treatment plan will deliver 385 cGy twice daily for 5 days for a total dose of 3850 cGy. An APBI plan that uses multicatheter brachytherapy will typically deliver 340 cGy over 5 days, twice daily, for a total dose of 3400 cGy. Alternatively, APBI can be delivered in a single fraction to the lumpectomy cavity intraoperatively to a dose of 18 to 21 Gy. Among these distinct RT techniques, interstitial multicatheter brachytherapy is the longest used and investigated method of delivery.36

Two studies used APBI in lieu of WBI (Table 2) in patients who underwent oncoplastic BCS.37,38 Roth et al investigated the feasibility and treatment results of interstitial multicatheter brachytherapy method after oncoplastic BCS.37 The local recurrence was 0.7% upon applying a total pulse dose rate of 50.4 Gy or high dose rate of 32 Gy over 4 days, suggesting the potential feasibility of APBI using interstitial multicatheter brachytherapy method in considering alternatives to WBI in selected low-risk patients.37 Massa et al investigated the use of IORT and conventionally fractionated external beam radiation after oncoplastic BCS.38 All patients in Massa et al reported favorable judgments on the aesthetic outcome with a score of 6 or higher on a scale of 0 (worst) to 10 (best). This score included factors such as aesthetic global result, breast symmetry, areola-nipple symmetry, and scarring.38 Although favorable cosmetic outcomes are achieved by the use of IORT in Massa et al, adjuvant APBI in the setting of oncoplastic rearrangement is still at experimental stage and its feasibility in lieu of WBI should be studied more in the future.

| Study                        | Patients receiving RT (%) | RT dose-fractionation (Gy) | Patients receiving boost RT (%) | Boost RT dose-fractionation (Gy) | Patient rating on cosmesis | Professional rating on cosmesis (%) | Local recurrence (%) | Distant recurrence (%) | Mortality (%) | Mean follow-up (mo, range) |
|------------------------------|---------------------------|---------------------------|---------------------------------|---------------------------------|---------------------------|-----------------------------------|---------------------|-----------------------|---------------|--------------------------|
| Tenofsky et al, 2014          | 93.1                      | —                         | —                               | 86.2% favorable                  | —                         | 0                                 | —                   | —                     | —             | 24.6 (2.9-44.7)          |
| Veiga et al, 2011             | 93.3                      | —                         | —                               | Mean 10 at 12 mo                | Mean 9.25 at 12 mo        | 6.6                               | 2.8                 | 47 (12-108)           | —             | —                       |
| Munhoz et al, 2011            | 100                       | Maximum 45-50 daily fx    | 100                             | 92.4% very satisfied            | 0                         | 5.9                               | 5.9                 | 36 (1-62)             | —             | —                       |
| Bamford et al, 2015           | 100                       | —                         | —                               | —                               | —                         | 2.3                               | 1.3                 | 39 (10-130)           | —             | —                       |
| Chang et al, 2012             | 94.9                      | Daily fx dosing up to total 45-50 | 100                             | —                               | —                         | 5.5                               | —                   | 48 (10-108)           | —             | —                       |
| Munhoz et al, 2009            | 100                       | Daily fx dosing up to total 45-50 | 100                             | —                               | —                         | 0                                 | —                   | 20 (5.79)             | —             | —                       |
| Munhoz et al, 2006            | 100                       | —                         | —                               | —                               | —                         | 12.8% poor in 2.5%            | —                   | —                     | —             | —                       |

BID, twice daily; fx, fraction; HDR, high dose rate; PDR, pulse dose rate; RT, radiation therapy.

* patients who received ERT

** patients who received IORT
Discussion

In this comprehensive literature review, the outcomes of oncoplastic BCS with adjuvant RT with and without boost were evaluated by assessing the local control and cosmetic sequelae. A total of 1194 potentially relevant publications were initially identified based on the previously discussed search criteria. After eliminating studies that did not meet secondary search criteria as detailed previously, 109 articles were initially identified. Of those, 41 were selected for this comprehensive review.

In patients who underwent oncoplastic BCS, the estimated probability of local recurrence when receiving conventionally fractionated whole breast radiation was 0.015 (95% CI, 0.008-0.03). Only 2 studies reported local recurrence rates in patients who underwent oncoplastic BCS followed by APBI, and none of the studies used hypofractionated whole breast radiation; as a result, a meaningful pooled probability estimate could not be calculated. Because of the lack of reports, a statistically significant conclusion regarding local control cannot be elucidated with respect to WBI compared with APBI. However, in an appropriately selected patient population who underwent oncoplastic BCS, APBI might represent an alternative treatment scheme in an investigational setting. There are significant challenges in accurately targeting the tumor bed for delivery of APBI after oncoplastic surgery, and in general, the use of oncoplastic BCS reduces the likelihood that APBI can be performed. Recently, a bioabsorbable 3-dimensional device with 6

---

Table 3  Outcomes of volume replacement and radiation therapy

| Study                  | Patients receiving ART (%) | ART dose-fractionation (Gy) | Patients receiving boost RT (%) | Boost RT dose-fractionation (Gy) | Patient rating on cosmesis | Professional rating on cosmesis | Local recurrence (%) | Distant recurrence (%) | Mortality (%) | Mean follow-up (mo, range) |
|------------------------|-----------------------------|----------------------------|---------------------------------|----------------------------------|----------------------------|-------------------------------|---------------------|-----------------------|----------------|-------------------------|
| Lee et al, 201462      | 64.3                        | —                          | —                               | —                                | 82.3% satisfaction (mean score, >4) | Mean 4.13                     | —                   | —                     | —             | 11.3 (4-23)              |
| Gendy et al, 200363    | 75.5                        | 50 Gy in 25 fx over 5 wk    | —                               | —                                | 83.5% average satisfaction       | 3.8                          | 4.1                  | —                     | —             | 53 (7-102)               |
| Losken et al, 200464   | 84.6                        | —                          | —                               | —                                | —                           | 5.1                          | 10.3                 | 5.1                   | —             | 44 (3-78)                |
| Bogusevicus et al, 201456 | 100                      | Maximum 50 (in 25 fx)       | 0                               | 0                                | 92.3% excellent/good            | 87.2% excellent/good         | 10                   | 38.3                  | 23.3          | 86                      |
| Down et al, 201369     | —                          | —                          | —                               | —                                | —                           | 0                            | —                   | —                     | —             | 29.3                    |
| Kronowitz et al, 200629 | 100                       | Minimum 50                 | 100                             | 10-15                            | —                           | 33% excellent/good (VR)       | 2                   | —                     | —             | 29                      |
| Tenofsky et al, 201457 | 93.1                        | —                          | —                               | —                                | 86.2% favorable                | —                            | 0                   | —                     | —             | 24.6 (2.9-44.7)         |
| Hamdi, 201370          | —                          | —                          | —                               | —                                | —                           | 1.7                          | —                   | —                     | —             | 48 (6-120)               |
| Veiga et al, 201141    | 93.3                        | —                          | —                               | —                                | Mean 10 at 12 mo               | Mean 9.25 at 12 mo            | 1                   | —                     | —             | —                      |
| Munhoz et al, 200973   | 100                        | Daily fx dosing up to total  | 100                             | 10                               | —                           | —                            | 5.5                  | —                     | —             | 48 (10-108)              |
| Munhoz et al, 200674   | 100                        | Daily fx dosing up to total  | 100                             | 10                               | Good or very good 88.2%, satisfactory in 8.8%, poor in 12.9% | —                            | 0                   | —                     | —             | 23                      |

ART, adjuvant radiation therapy. See Tables 1 and 2 for other abbreviations.
permanent titanium clips (Biozorb, Focal Therapeutics, Aliso Viejo, CA) has been developed for use in oncoplastic reconstruction. Not only does this device allow for oncoplastic breast surgery, it also provides the radiation oncologist with specific landmarks for targeting of boost RT or APBI. Currently, a registry trial is under way to determine the cosmetic and local control benefits of the device.

Professional and patient satisfaction ratings were investigated with respect to WBI and APBI. In patients who underwent WBI, the overall estimated probability of satisfaction based on professional ratings was 0.877 (95% CI, 0.784-0.934). The overall estimated probability of satisfaction based on patient ratings was 0.913 (95% CI, 0.815-0.962). Patient-rated cosmesis in patients who underwent oncoplastic BCS followed by APBI was only available in the report by Massa et al. Of interest, all patients in Massa et al reported favorable judgments on the aesthetic outcome with a score of 6 or higher on a scale of 0 (worst) to 10 (best). Previous studies have reported unacceptable cosmetic outcomes related to the use of APBI in patients who did not undergo oncoplastic BCS. The differences in these conclusions suggest that further data may need to be generated before definitive conclusions are drawn.

The effect of the boost on cosmesis was also reported by both professionals and patients. The overall estimated probability of satisfaction from professional cosmetic ratings was 0.849 (95% CI, 0.645-0.946) and 0.936 (95% CI, 0.63-0.999) with and without boost, respectively. The estimated probability of satisfaction from patient cosmetic rating was 0.89 (95% CI, 0.596-0.979) and 0.84 (95% CI, 0.1-0.996) with and without the boost, respectively.

This review is subject to the typical limitations of comprehensive reviews. Differences in reporting patterns of local recurrences as well as time frames of reporting to local recurrences and time frames of reporting to local control with respect to each modality. In 2 studies, a local recurrence was reported without a given follow-up period.40,41 Local recurrence rates without consistency in the follow-up period further raise the difficulty of making a comparison across studies and generating an assessment of the efficacy of different surgical methods and radiation treatments.

Furthermore, studies that reported cosmesis used methodologies that ranged from the Radiation Therapy Oncology Group Quality of Life Baseline Questionnaire, to pre- and postoperative photographs, and subjective assessments by patients and professional staff. In addition, the scoring system in each methodology widely varied, such as 0% to 100% satisfaction, acceptable versus unacceptable, and excellent/good/satisfactory/poor. The only standardization involved in methodology was the 5 parameters that were used in the cosmesis assessment: breast shape, symmetry, scars, nipple areola complex position and shape, and post-irradiation sequelae. The differences in the methodology diminish the possibility of establishing a meaningful comparison across studies.

Oncoplastic BCS with adjuvant RT is an emerging area of clinical investigation, and future studies might benefit from adopting a more consistent and standardized reporting of data to better determine the optimal RT treatments for patients undergoing oncoplastic BCS. In addition, future prospective study should be designed to better understand the impact of oncoplastic surgery on radiation technique and local recurrence. Finally, because oncoplastic techniques may impact the type of radiation treatment the patient may ultimately receive, a preoperative referral to radiation oncology should be strongly considered. The radiation oncologist may request clips to better delineate the cavity, can comment on the clinical benefit of the boost in the individual patient, and can discuss the impact of the technique on fractionation scheme, to allow the patient to make an informed decision about the oncoplastic approach.

References

1. van Dongen JA, Voogd AC, Fentiman IS, et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst. 2000;92(14):1143-1150.
2. Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347(16):1227-1232.
3. Asgeirsson KS, Rasheed T, McCulley SJ, Macmillan RD. Oncological and cosmetic outcomes of oncoplastic breast conserving surgery. Eur J Surg Oncol. 2005;31(8):817-823.
4. Engel J, Kerr J, Schlesinger-Raab A, Sauer H, Holzel D. Quality of life following breast-conserving therapy or mastectomy: results of a 5-year prospective study. Breast J. 2004;10(3):223-231.
5. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Eng J Med. 2002;347(16):1233-1241.
6. Fisher ER, Anderson S, Redmond C, Fisher B. Ipsilateral breast tumor recurrence and survival following lumpectomy and irradiation: Pathological findings from NSABP protocol B-06. Semin Surg Oncol. 1992;8(3):161-166.
7. Zucca-Matthes G, Manconi A, da Costa Viera RA, Michelli RA, Matthes Ado C. The evolution of mastectomies in the oncoplastic breast surgery era. Gland Surg. 2013;2(2):102-106.
8. Mansfield L, Agrawal A, Cutress RI. Oncoplastic breast conserving surgery. Gland Surg. 2013;2(3):158-162.
9. Koilas J, Davies G, Bochner MA, Gill PG. Clinical impact of oncoplastic surgery in a specialist breast practice. ANZ J Surg. 2008;78(4):269-272.
10. Whelan TJ. Use of conventional radiation therapy as part of breast-conserving treatment. J Clin Oncol. 2005;23(8):1718-1725.
11. Schaverien MV, Stallard S, Dodwell D, Doughty JC. Use of boost radiotherapy in oncoplastic breast-conserving surgery - a systematic review. Eur J Surg Oncol. 2013;39(11):1179-1185.
12. Chakravorty A, Shrestha AK, Sannugalingam N, et al. How safe is oncoplastic breast conservation? Comparative analysis with standard breast conserving surgery. *Eur J Surg Oncol*. 2012;38(5):395-398.

13. Kaur N, Petit JY, Rietjens M, et al. Comparative study of surgical margins in oncoplastic surgery and quadrantectomy in breast cancer. *Ann Surg Oncol*. 2005;12(7):539-545.

14. Kacprowska A, Jassem J. Hypofractionated radiotherapy for early breast cancer: Review of phase III studies. *Rep Pract Oncol Radiother*. 2012;17(2):66-70.

15. Clough KB, Lewis JS, Couturaud B, Fitoussi A, Nos C, Falcou MC. Oncoplastic techniques allow extensive resections for breast-conserving therapy of breast carcinomas. *Ann Surg*. 2003;237(1):26-34.

16. Bartelink H, Horiot JC, Poortmans PM, et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. *J Clin Oncol*. 2007;25(22):3259-3265.

17. Bartelink H, Horiot JC, Poortmans P, et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. *N Engl J Med*. 2001;345(19):1378-1387.

18. Antonini N, Jones H, Horiot JC, et al. Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881-10882. *Radiother Oncol*. 2007;82(3):265-271.

19. Vrielin C, Collette L, Fourquet A, et al. Can patient-, treatment- and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients? *Eur J Cancer*. 2003;39(7):932-944.

20. Early Breast Cancer Trialists’ Collaborative G, Darby S, McGale P, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. *Lancet*. 2011;378(9804):1707-1716.

21. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. *Lancet*. 2005;366(9503):2087-2106.

22. de Bock GH, van der Hage JA, Putter H, Bonnema J, Bartelink H, van de Velde CJ. Isolated loco-regional recurrence of breast cancer is more common in young patients and following breast conserving therapy: long-term results of European Organisation for Research and Treatment of Cancer studies. *Eur J Cancer*. 2006;42(3):351-356.

23. Elkuizen PH, van de Vijver MJ, Hermans J, van de Velde CJ, Leer JW. Local recurrence after breast-conserving therapy for invasive breast cancer: high incidence in young patients and association with poor survival. *Int J Radiat Oncol Biol Phys*. 1998;40(4):859-867.

24. Margenthaler JA. Optimizing conservative breast surgery. *J Surg Oncol*. 2011;103(4):306-312.

25. Pezner RD. The oncoplastic breast surgery challenge to the local radiation boost. *Int J Radiat Oncol Biol Phys*. 2011;79(4):963-964.

26. Vrielin C, Collette L, Fourquet A, et al. The influence of the boost in breast-conserving therapy on cosmetic outcome in the EORTC “boost versus no boost” trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. European Organization for Research and Treatment of Cancer. *Int J Radiat Oncol Biol Phys*. 1999;45(3):677-685.

27. Vrielin C, Collette L, Fourquet A, et al. The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC ‘boost vs. no boost’ trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. *Radiother Oncol*. 2000;55(3):219-232.

28. Tan MP. Alternatives for optimizing outcomes in oncoplastic breast surgery. *Ann Surg Oncol*. 2012;19(7):2327-2333.

29. Kronowitz SJ, Feedly JA, Hunt KK, et al. Determining the optimal approach to breast reconstruction after partial mastectomy. *Plast Reconstr Surg*. 2006;117(1):1-11. discussion 12-14.

30. Chang DW, Youssef A, Cha S, Reeree GP. Autologous breast reconstruction with the extended latissimus dorsi flap. *Plast Reconstr Surg*. 2002;110(3):751-759. discussion 760-751.

31. Yang JD, Lee JW, Cho YK, et al. Surgical techniques for personalized oncoplastic surgery in breast cancer patients with small- to moderate-sized breasts (part 2): volume replacement. *J Breast Cancer*. 2012;15(1):7-14.

32. Silverstein MJ, Savalia N, Khan S, Ryan J. Extreme oncoplasty: breast conservation for patients who need mastectomy. *Breast J*. 2015;21(1):52-59.

33. Romestain P, Lehingue Y, Carrie C, et al. Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France. *J Clin Oncol*. 1997;15(3):963-968.

34. Shah C, Vicini F, Wazer DE, Arthur D, Patel RR. The American Brachytherapy Society consensus statement for accelerated partial breast irradiation. *Brachytherapy*. 2013;12(4):267-277.

35. Goyal S, Daroui P, Khan AJ, Kearney T, Kirstein L, Haffty BG. Three-year outcomes of a once daily fractionation scheme for accelerated partial breast irradiation (APBI) using 3-D conformal radiotherapy (3D-CRT). *Cancer Med*. 2013;2(6):964-971.

36. Smith BD, Arthur DW, Buchholz TA, et al. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). *J Am Coll Surg*. 2009;209(2):269-277.

37. Roth AM, Kauer-Dorner D, Resch A, et al. Is oncoplastic surgery a contraindication for accelerated partial breast radiation using the interstitial multicatheter brachytherapy method? *Brachytherapy*. 2014;13(4):394-399.

38. Massa M, Meszaros P, Baldelli I, Bisso N, Franchelli S. Aesthetic evaluation in oncoplastic and conservative breast surgery: a comparative analysis. *Plast Reconstr Surg Glob Open*. 2015;3(3):e339.

39. Jagsi R, Ben-David MA, Moran JM, et al. Unacceptable cosmesis in a protocol investigating intensity-modulated radiotherapy with active breathing control for accelerated partial-breast irradiation. *Int J Radiat Oncol Biol Phys*. 2010;76(1):71-78.

40. Chang E, Johnson N, Webber B, et al. Bilateral reduction mammaplasty in combination with lumpectomy for treatment of breast cancer in patients with macromastia. *Am J Surg*. 2004;187(5):647-650. discussion 650-641.

41. Veiga DF, Veiga-Filho J, Ribeiro LM, et al. Evaluations of aesthetic outcomes of oncoplastic surgery by surgeons of different gender and specialty: a prospective controlled study. *Breast*. 2011;20(5):407-412.

42. Yang JD, Bae SG, Chung HY, Cho BC, Park HY, Jung JH. The usefulness of oncoplastic volume displacement techniques in the superiorly located breast cancers for Korean patients with small to moderate-sized breasts. *Ann Plast Surg*. 2011;67(5):474-480.

43. Ballester M, Berry M, Coutraud B, Reyal F, Salmon RJ, Fitoussi AD. Lateral mammaplasty reconstruction after surgery for breast cancer. *Br J Surg*. 2009;96(10):1141-1146.

44. Ragenth CJ, Tausch C. Intramammarian flap reconstruction (IFR) technique in breast conserving surgery. *Breast*. 2009;18(6):387-392.

45. Maguire PD, Adams A, Nichols MA. Oncoplastic Surgery and Radiation Therapy for Breast Conservation: Early Outcomes. *Am J Clin Oncol*. 2013;353-357.

46. Khafagy M, Fakhri I, Hamed A, Youssef O. Pedicled dermoglandular flap reconstruction following breast conserving surgery. *J Egypt Natl Canc Inst*. 2012;24(2):91-96.

47. Egro FM, Pinell-White X, Hart AM, Losken A. The use of reduction mammaplasty with breast conservation therapy: an analysis of timing and outcomes. *Plast Reconstr Surg*. 2015;135(6):963e-971e.
48. Goffman TE, Schneider H, Hay K, Elkins DE, Schnarrs RA, Carman C. Cosmesis with bilateral mammoreduction for conservative breast cancer treatment. *Breast*. 2005;11(3):195-198.

49. Munhoz AM, Montag E, Arruda EG, et al. Critical analysis of reduction mammoplasty techniques in combination with conservative breast surgery for early breast cancer treatment. *Plast Reconstr Surg*. 2006;117(4):1091-1103. discussion 1104-1097.

50. Losken A, Styblo TM, Carlson GW, Jones GE, Amerson BJ. Management algorithm and outcome evaluation of partial mastectomy defects treated using reduction or mastopexy techniques. *Ann Plast Surg*. 2007;59(3):235-242.

51. McCulley SJ, Macmillan RD. Therapeutic mammoplasty—analysis of 50 consecutive cases. *Br J Plast Surg*. 2005;58(7):902-907.

52. Nos C, Fitoussi A, Bourgeois D, Fourquet A, Salmon RJ, Clough KB. Conservative treatment of lower pole breast cancers by bilateral mammoplasty and radiotherapy. *Eur J Surg Oncol*. 1998;24(6):508-514.

53. Fitoussi AD, Berry MG, Fama F, et al. Oncoplastic breast surgery for cancer: analysis of 540 consecutive cases [outcomes article]. *Plast Reconstr Surg*. 2010;125(2):454-462.

54. Meretoja TJ, Svarvar C, Jahkola TA. Outcome of oncoplastic breast surgery in 90 prospective patients. *Am J Surg*. 2010;200(2):224-228.

55. Grubnik A, Benn C, Edwards G. Therapeutic mammoplasty for breast cancer: oncological and aesthetic outcomes. *World J Surg*. 2013;37(1):72-83.

56. Bogusevicius A, Cepuliene D, Sepetauskiene E. The integrated evaluation of the results of oncoplastic surgery for locally advanced breast cancer. *Breast*. 2014;20(1):53-60.

57. Tenofsky PL, Dowell P, Topalovski T, Helmer SD. Surgical, oncologic, and cosmetic differences between oncoplastic and non-oncoplastic breast conserving surgery in breast cancer patients. *Am J Surg*. 2014;207(3):398-402. discussion 402.

58. Munhoz AM, Aldrighi CM, Montag E, et al. Outcome analysis of immediate and delayed conservative breast surgery reconstruction with mammoplasty and reduction mammoplasty techniques. *Ann Plast Surg*. 2011;67(3):220-225.

59. Munhoz AM, Montag E, Arruda EG, et al. Superior-medial dermoglandular pedicle reduction mammoplasty for immediate conservative breast surgery reconstruction: technical aspects and outcome. *Ann Plast Surg*. 2006;57(5):502-508.

60. Nizet JL, Maweja S, Lakosi F, et al. Oncological and surgical outcome after oncoplastic breast surgery. *Acta Chir Belg*. 2015;115(1):33-41.

61. Canuso F, Catanuto G, De Meo L, et al. Outcomes of bilateral mammoplasty for early stage breast cancer. *Eur J Surg Oncol*. 2008;34(10):1143-1147.

62. Lee JW, Kim MC, Park HY, Yang JD. Oncoplastic volume replacement techniques according to the excised volume and tumor location in small- to moderate-sized breasts. *Gland Surg*. 2014;3(1):14-21.

63. Gendy RK, Able JA, Rainsbury RM. Impact of skin-sparing mastectomy with immediate reconstruction and breast-sparing reconstruction with miniflaps on the outcomes of oncoplastic breast surgery. *Br J Surg*. 2003;90(4):433-439.

64. Losken A, Schaefer TG, Carlson GW, Jones GE, Styblo TM, Bostwick J 3rd. Immediate endoscopic latissimus dorsi flap: risk or benefit in reconstructing partial mastectomy defects. *Ann Plast Surg*. 2004;53(1):1-5.

65. Eaton BR, Losken A, Okwan-Duodu D, et al. Local recurrence patterns in breast cancer patients treated with oncoplastic reduction mammoplasty and radiotherapy. *Ann Surg Oncol*. 2014;21(1):93-99.

66. Schrenk P, Huemer GM, Sir A, Moser F, Wayand W. Tumor quadrantectomy combined with reduction mammoplasty for the treatment of breast cancer. *European Surgery*. 2006;38(6):424-432.

67. Caruso F, Ferrara M, Castiglione G, et al. Therapeutic mammoplasties: full local control of breast cancer in one surgical stage with frozen section. *Eur J Surg Oncol*. 2011;37(10):871-875.

68. Rietjens M, Urban CA, Rey PC, et al. Long-term oncological results of breast conservative treatment with oncoplastic surgery. *Breast*. 2007;16(4):387-395.

69. Down SK, Jha PK, Burger A, Hussien MI. Oncological advantages of oncoplastic breast-conserving surgery in treatment of early breast cancer. *Breast*. 2013;19(1):56-63.

70. Hamdi M. Oncoplastic and reconstructive surgery of the breast. *Breast*. 2013;22(Suppl 2):S100-S105.

71. Bamford R, Sutton R, McIntosh J. Therapeutic mammoplasty allows for clear surgical margins in large and multifocal tumours without delaying adjuvant therapy. *Breast*. 2015;24(2):171-174.

72. Chang EI, Peled AW, Foster RD, et al. Evaluating the feasibility of extended partial mastectomy and immediate reduction mammoplasty reconstruction as an alternative to mastectomy. *Ann Surg*. 2012;255(6):1151-1157.

73. Munhoz AM, Montag E, Arruda E, et al. Immediate reconstruction following breast-conserving surgery: management of the positive surgical margins and influence on secondary reconstruction. *Breast*. 2009;18(1):47-54.

74. Munhoz AM, Montag E, Arruda EG, et al. The role of the lateral thoracodorsal fasciocutaneous flap in immediate conservative breast surgery reconstruction. *Plast Reconstr Surg*. 2006;117(6):1699-1710.